Months after $10M Series A, rare disease AI upstart Healx hauls in $56M in fresh funding
In 2010, Nick Sireau quit his job to focus solely on the patient group he had set up to help his sons diagnosed with a rare genetic disease called alkaptonuria (AKU). Researchers had found a feasible treatment from an unlikely source: a weedkiller, but it was being used to help infants with a different disorder. Sireau would then confront the perils of the traditional trial-and-error drug discovery process that demands time and money.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters
